D.A. Davidson & CO. Reduces Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

D.A. Davidson & CO. lowered its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 9.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,770 shares of the company’s stock after selling 1,480 shares during the quarter. D.A. Davidson & CO.’s holdings in Intellia Therapeutics were worth $172,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after purchasing an additional 794 shares in the last quarter. Capstone Investment Advisors LLC lifted its position in Intellia Therapeutics by 1.4% during the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock valued at $1,256,000 after buying an additional 831 shares during the period. KBC Group NV boosted its holdings in shares of Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after buying an additional 1,020 shares in the last quarter. Axxcess Wealth Management LLC grew its position in shares of Intellia Therapeutics by 5.4% in the 3rd quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock worth $415,000 after buying an additional 1,044 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Intellia Therapeutics by 10.3% in the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock worth $320,000 after acquiring an additional 1,538 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on NTLA shares. William Blair reiterated a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research note on Monday, November 18th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Barclays lowered their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Chardan Capital upped their target price on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research note on Monday, November 18th. Finally, Wells Fargo & Company dropped their price target on Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.71.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 29,000 shares of company stock valued at $352,551 over the last 90 days. 3.20% of the stock is owned by company insiders.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $10.86 on Friday. The company’s 50-day moving average is $10.92 and its two-hundred day moving average is $15.75. Intellia Therapeutics, Inc. has a 1-year low of $8.96 and a 1-year high of $34.87. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -2.00 and a beta of 1.80.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.